AIDX
20/20 Biolabs, Inc. Common Stock
NASDAQ · Healthcare · Medical - Devices · US
$0.59
−3.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$7.55M
MomentumView details →
1D Return
−3.27%
YTD Return
—
RSI (14)
54.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$7.55M
RSI (14)
54.3
MomentumView details →
1D Return
−3.27%
YTD Return
—
Similar companies
Latest newsMore news →
BioLabs announced Carmen Schicklberger as site director for BioLabs Rochester, MN, and Geof Hannigan as Mayo Clinic's director of startup engagement.2d agoBioLabs Rochester, MN announced it will open its 17,000-square-foot shared laboratory and office facility in September 2026, with recruitment underway for resident companies.2d ago20/20 BioLabs reported its financial results for the second quarter ended June 30, 2026, with record quarterly revenue from its flagship multi-cancer early detection test, OneTest revenue up 47% year-over-year to $0.7 million, gross profit up 87% to $0.3 million, gross margin expanding to 41.7% from 30.5%, and cash position strengthened to $4.5 million with all convertible note debt eliminated during the quarter.18d ago